Figure 1.

Rosiglitazone stimulates the expression and secretion of ANGPTL4 via PPARγ. (a–c) HTR8/SVneo cells, HUVECs and placental explants were stimulated with Rosi (rosiglitazone) (0, 0.25, 0.5 and 1 μM) for 18 h. The expression of PPARγ and ANGPTL4 and the secretion of ANGPTL4 were determined by quantitative real-time PCR (qRT-PCR), western blot and enzyme-linked immunosorbent assay (ELISA). The data are shown as the means±S.E.M. *P<0.05, **P<0.01 and ***P<0.001 compared with control. (d) HUVECs, HTR8/SVneo cells and placental explants were stimulated with different concentrations (0 and 1 μM) of rosiglitazone for 18 h, and then stained to detect the expression of PPARγ and ANGPTL4 by immunofluorescence. (e–h) HTR8/SVneo cells, HUVECs and placental explants were transfected with control siRNA (si-Con) or PPARγ siRNA (si-PPARγ), and then treated with 1 μM rosiglitazone for 18 h. The expression of PPARγ and ANGPTL4 and the secretion of ANGPTL4 were evaluated by qRT-PCR, western blot analysis, ELISA and immunofluorescence. The data are shown as the means±S.E.M. **P<0.01 relative to corresponding control